Swiss biopharmaceutical company Debiopharm has entered into a partnership with WhiteLab Genomics to advance drug target identification and design in oncology.
WhiteLab Genomics, which operates from Paris and Boston, specialises in using artificial intelligence (AI) for research and development (R&D) in genomic medicine.
The primary aim of this collaboration is to identify receptors that are overexpressed on the surface of cancer cells. These cancer-specific receptors will serve as the initial targets for the development of new therapeutic agents.
The next step will involve identifying lead candidates that can bind effectively to these receptors. Once identified, these agents will be attached to the surface of lipid nanoparticles to improve active tissue targeting.
As per the parties, lipid nanoparticles have emerged as a leading vector for drug delivery, with the potential to significantly impact the field of oncology, especially genomic medicine, due to their high delivery efficiency. However, a major challenge with lipid nanoparticles is their tendency to accumulate in non-target organs, such as the liver, which restricts their ability to reach the desired site.
To address this issue, WhiteLab Genomics plans to use its AI-powered platform to explore new in silico methods to enhance the targeted delivery capabilities of lipid nanoparticles, opening up new avenues for therapeutic applications.
Debiopharm CEO Betrand Ducrey said: “As a company specialised in drug development, we know the hardships of the field and therefore we recognise the added value of AI powered platforms like the WhiteLab Genomics’ platform applied to the early stages of drugs R&D.
“We look forward to fully exploiting the potential of AI based solutions to develop drugs, de-risk assets, de-risk any toxicity, and ensure that we bring the most efficacious and personalised drugs to patients.”
As a major investor in WhiteLab Genomics, Debiopharm is said to have consistently supported the former’s innovative approaches and solutions through its Innovation Fund. This collaboration aims to present a valuable opportunity to validate the potential of WhiteLab Genomics’ AI platform and to further strengthen the ongoing relationship between the two companies.
WhiteLab Genomics CEO and co-founder David Del Bourgo said: “WhiteLab’s innovative AI platform represents a significant advancement in the field of targeted cancer therapy. By improving the specificity and delivery of lipid nanoparticles, we aim to provide more effective treatments for patients suffering from hormonal cancers.
“Our collaboration with a leading player such as Debiopharm further demonstrates our focus on developing cutting-edge solutions that have the potential to transform cancer treatments.”
